Filing Details

Accession Number:
0000912282-17-000051
Form Type:
13G Filing
Publication Date:
2017-02-14 13:20:00
Filed By:
Mmcap International Inc. Spc
Company:
Immune Pharmaceuticals Inc (NASDAQ:IMNPQ)
Filing Date:
2017-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
MMCAP International Inc. SPC 2,637,034 1.99%
MM Asset Management Inc 2,637,034 1.99%
Filing

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 

SCHEDULE 13G

Amendment No. 2

INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934

IMMUNE PHARMACEUTICALS INC
(Name of Issuer)

 
COMMON STOCK
(Title of Class of Securities)

 
45254C101
(CUSIP Number)


December 31, 2016
(Date of Event Which Requires Filing of This Statement)


Check the Appropriate box to designate the rule pursuant to which this schedule is filed:

☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)


CUSIP No. 45254C101
13G
Page 2 of 6 Pages
 
1
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
 
MMCAP International Inc. SPC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) 
(b)     ☐
 
     
3
SEC USE ONLY
 
     
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Cayman Islands
 
5
SOLE VOTING POWER
NUMBER OF
 
0
SHARES
6
SHARED VOTING POWER
BENEFICIALLY
 
2,637,034*
OWNED BY
7
SOLE DISPOSITIVE POWER
EACH
 
0
REPORTING
8
SHARED DISPOSITIVE POWER
PERSON WITH
 
2,637,034*
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,637,034*
*The reporting persons own 1,230,487 common shares, Series A warrants convertible into 520,833 common shares, Series B warrants convertible into 535,714 common shares, Series C warrants convertible into 100,000 common shares and Series D warrants convertible into 250,000 common shares.
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 
 
     
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
1.99%**
**The percentages used herein are calculated based upon 131,291,362 outstanding shares of the Issuer as of November 17, 2016, plus 1,406,547 common shares in aggregate underlying warrants which are beneficially owned by the reporting persons and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.
12
TYPE OF REPORTING PERSON*
 
CO
*SEE INSTRUCTIONS BEFORE FILLING OUT!
 

CUSIP No. 45254C101
13G
Page 3 of 6 Pages
 
1
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
 
MM Asset Management Inc.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) 
(b) 
 
     
3
SEC USE ONLY
 
     
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Ontario, Canada
 
5
SOLE VOTING POWER
NUMBER OF
 
0
SHARES
6
SHARED VOTING POWER
BENEFICIALLY
 
2,637,034*
OWNED BY
7
SOLE DISPOSITIVE POWER
EACH
 
0
REPORTING
8
SHARED DISPOSITIVE POWER
PERSON WITH
 
2,637,034*
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,637,034*
*The reporting persons own 1,230,487 common shares, Series A warrants convertible into 520,833 common shares, Series B warrants convertible into 535,714 common shares, Series C warrants convertible into 100,000 common shares and Series D warrants convertible into 250,000 common shares.
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 
 
     
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
1.99%**
**The percentages used herein are calculated based upon 131,291,362 outstanding shares of the Issuer as of November 17, 2016, plus 1,406,547 common shares in aggregate underlying warrants which are beneficially owned by the reporting persons and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.
12
TYPE OF REPORTING PERSON*
 
CO
*SEE INSTRUCTIONS BEFORE FILLING OUT!
 

CUSIP No. 45254C101
13G
Page 4 of 6 Pages

 
Item 1(a).
Name of Issuer:

Immune Pharmaceuticals Inc.

Item 1(b).
Address of Issuer’s Principal Executive Offices:

430 East 29th Street, Suite 940
New York, NY 10016

Item 2(a).
Name of Person Filing:

i) MMCAP International Inc. SPC
ii)       MM Asset Management Inc.

Item 2(b).
Address of Principal Business Office or, if None, Residence:

i)      P. O. Box 259
 George Town Financial Centre
Grand Cayman, Cayman Islands KY1-1208

ii)     66 Wellington Street West, Suite 2707
 Toronto, Ontario M5K 1H6 Canada

Item 2(c).
Citizenship:

i) Cayman Islands
ii)       Ontario, Canada

Item 2(d).
Title of Class of Securities:

Common Stock

Item 2(e).
CUSIP Number:

45254C101

Item 3.
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
 
(a) ☐
Broker or dealer registered under Section 15 of the Act;
(b) ☐
Bank as defined in Section 3(a)(6) of the Act;
(c) ☐
Insurance Company as defined in Section 3(a)(19) of the Act;
(d) ☐
Investment Company registered under Section 8 of the Investment Company Act;
(e) ☐
Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f)  ☐
Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);
(g) ☐
Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);
(h) ☐
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
(i)  ☐
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940:
(j)  ☐
Group, in accordance with Rule 13d-1(b)(1)(ii)(j).
If this statement is filed pursuant to Rule 13d-1(c), check this box.

CUSIP No. 45254C101
13G
Page 5 of 6 Pages

 
Item 4.
Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1.

(a) Amount beneficially owned:  2,637,034*

(b) Percent of class:  1.99%**

(c) Number of shares as to which such person has:

     (i)
Sole power to vote or to direct the vote:  0

     (ii)
Shared power to vote or to direct the vote:  2,637,034*

     (iii)
Sole power to dispose or to direct the disposition of:  0

     (iv)
Shared power to dispose or to direct the disposition of:  2,637.034*

*The reporting persons own 1,230,487 common shares, Series A warrants convertible into 520,833 common shares, Series B warrants convertible into 535,714 common shares, Series C warrants convertible into 100,000 common shares and Series D warrants convertible into 250,000 common shares.

**The percentages used herein are calculated based upon 131,291,362 outstanding shares of the Issuer as of November 17, 2016, plus 1,406,547 common shares in aggregate underlying warrants which are beneficially owned by the reporting persons and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.


Instruction.  For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1).

Item 5.
Ownership of Five Percent or Less of a Class.

If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [XX ].

Item 6.
Ownership of More than Five Percent on Behalf of Another Person.

N/A

Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

N/A

Item 8.
Identification and Classification of Members of the Group.

N/A

Item 9.
Notice of Dissolution of Group.

N/A
 
 

CUSIP No. 45254C101
13G
Page 6 of 6 Pages

 
Item 10.  Certification.  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.




SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.



 
February 14, 2017
 
(Date)
   
 
MMCAP International Inc. SPC
 
 
 
 
By: /s/ Matthew MacIssac                 
Matthew MacIsaac, Director
   
   
 
February 14, 2017
 
(Date)
   
 
MM Asset Management Inc.
 
 
 
 
By:  /s/ Hillel Meltz                             
Hillel Meltz, President